CARDIFF UNIVERSITY
STANDARD OPERATING PROCEDURE FOR THE USE OR
STORAGE OF HUMAN TISSUE FOR THE PURPOSES OF
RESEARCH
TRANSPORTATION OF HUMAN TISSUE
SOP Number: CU/09/HTA 05/3.0
Version Number & Date: 3.0 & Jan 2013
Superseded Version Number and Date:
Effective Date:
09 Jan 2013
Review Date:
09 Jan 2014
CU/11/HTA 05/2.0
July 2011
Author:
Position:
Carina Hibbs
HTA Governance
Officer, GOVRN
____________________
Sharon Orton
HTA Co-ordinator,
GOVRN
____________________
Signature
Approved by:
Date
Position:
Professor Jonathan Bisson DI – Licence No 12422 ____________________
Signature
Date
Disclaimer
When using this document, please ensure that the version you are using is the most up to
date either by checking on the GOVRN/HTA website for any new versions or contact the
HTA Governance Officer to confirm the current version.
Out of date documents must not be relied upon and should be destroyed.
CU/09/HTA 05/3.0
Page 1 of 16
Version
Number
1.0
2.0
Changes to Document
Changes
authored by
Carina Hibbs
Minor changes were made including
formatting and alteration of
wording/definitions.
Contact information updated
Substantial changes:
Carina Hibbs
 Addition of ‘Licensing’ and
‘Consent’ sections;
 Inclusion of detailed information
about transportation of infectious
substances and dangerous goods.
Date Approved
14/06/2011
09/01/2013
Contact information updated
Reinstated original document numbering
(eg CU/09/HTA x/3.0 as opposed the
incorrect CU/11/HTA x/2.0 as previously
numbered)
CU/09/HTA 05/3.0
Page 2 of 16
CONTENTS PAGE
1.
2.
3.
4.
5.
Background
Purpose
Responsible Personnel
Definitions
Procedure
5.1 HTA Licensing
5.2 Consent
5.3 Health and Safety Issues in Transporting Human Tissues
5.4 Transportation Records and Documentation
5.5 Transport Regulations – Infectious Substances
5.6 Containment/Packaging
5.7 Containment Labelling and Documentation
5.8 Dangerous Goods and Packing Instructions
5.9 Transportation Methods
6. References
7. Referenced SOPs
8. Contacts
Appendix A
WHO Flowchart for the Classification of
Infectious Substances and Patient Samples
Acknowledgements
The World Health Organization Guidance on Regulation for the
Transport of Infectious Substances 2011-2012, excerpts from which
appear in this SOP.
CU/09/HTA 05/3.0
Page 3 of 16
1
BACKGROUND
The Human Tissue Act 2004 (HT Act) came in to force fully on 1 September 2006.
The aim of the HT Act is to provide a legal framework regulating the storage and use
of human tissue from the living and the removal storage and use of tissue from the
deceased. It introduces regulation of other activities like post mortem examinations,
and the storage of human material for education, training and research. It is intended
to achieve a balance between the rights and expectations of individuals and families,
and broader considerations, such as the importance of research, education, training,
pathology and public health surveillance to the population as a whole.
The HT Act set up the Human Tissue Authority (HTA) which issues licences for a
number of licensable activities under the HT Act. Cardiff University is the Licence
Holder for an Anatomy, Human Application and a Research Hub and Satellite
Licence. This SOP applies to the research hub and satellite licences.
2
PURPOSE
The purpose of this Standard Operating Procedure (SOP) is to ensure that staff
involved in research covered by the HT Act understand the procedure and
mechanisms for the transportation of human tissue.
3
RESPONSIBLE PERSONNEL
This SOP applies to all Cardiff University and UHB staff responsible for the
transportation of human tissue for research.
Chief Investigators/Research Supervisors are responsible for ensuring that this
SOP is correctly applied in the conduct of research and that each researcher takes
individual responsibility for applying this SOP when required to do so.
Individual members of staff will be responsible for ensuring that this SOP is
correctly applied when collecting, using or storing human tissue for teaching
purposes.
Governance and Compliance Division is responsible for ensuring that this SOP
remains fit for purpose.
4
DEFINITIONS
Category A Infectious Substance – An infectious substance which is transported in
a form that, when exposure to it occurs, is capable of causing permanent disability,
life-threatening or fatal disease in otherwise healthy humans or animals.
Category B Infectious Substance – An infectious substance that does not meet the
criteria for inclusion in Category A.
Chief Investigator (CI) – is the appropriately qualified individual who has
responsibility for the conduct of the study.
Exempt Human Specimen – Human specimens for which there is minimal likelihood
that pathogens are present.
CU/09/HTA 05/3.0
Page 4 of 16
Human Tissue – Any and all constituent parts of the human body formed by cells.
The Human Tissue Authority has issued a Supplementary List of Materials which
contains additional information.
Human Tissue Authority (HTA) – The governing body set up to regulate activities
that come under the HT Act. The HTA is a watchdog that supports public confidence
by licensing organisations that store and use human tissue for purposes such as
research, patient treatment, post-mortem examination, teaching, and public
exhibitions.
Material Transfer Agreement (MTA) – a contract that governs the transfer of
research materials between two organisations when the recipient intends to use the
material for their own research.
National Research Ethics Service (NRES) – NRES is the core function of the
Health Research Authority (HRA) which was established on 01 December 2011. It
provides an efficient and robust ethics review service and has a dual mission:


to protect the rights, safety, dignity and well-being of research participants,
to facilitate and promote ethical research that is of potential benefit to
participants, science and society.
Person Designate (PD) – A person to whom the licence applies and to whom the
authority conferred by the licence extends. Each School/Institute operating under an
HTA Licence should have at least one Person Designate.
Relevant Material – Any material, other than gametes, removed from the body which
consists of or includes human cells. In the HT Act references to relevant material
from a human body do not include:
 embryos outside the human body,
 hair and nail from the body of a living person,
 cell lines or any other human material created outside the human body,
 serum, DNA and RNA.
See Cardiff University HTA Standard Operating Procedure for Obtaining Informed
Consent for the HTA Supplementary List of Materials.
Standard Operating Procedure (SOP) – Detailed, written instructions to achieve
uniformity of performance of a specific function.
CU/09/HTA 05/3.0
Page 5 of 16
5
PROCEDURE
5.1
HTA Licensing
5.1.1
In order to transport relevant material legally between two establishments within
England, Wales and Northern Ireland both must have an HTA Licence, unless one of
the following exemptions applies:
a) Transportation of the tissue is covered by project specific NRES approval;
b) The distributing establishment sends the tissue off site within 7 days and the
receiving establishment has an HTA Licence or one of the exemptions
applies;
c) The receiving establishment renders the tissue acellular as a result of
processing within 7 days and the distributing establishment has an HTA
Licence or one of the exemptions applies;
d) The tissue is distributed for use in a specific research project from a Research
Tissue Bank (RTB) with generic NRES approval and the RTB is held on HTA
Licensed premises;
e) The tissue is not relevant material, e.g. the tissue is acellular;
f) The relevant material is more than 100 years old.
5.1.2
Evidence of an HTA Licence or the exemption must be provided before the tissue is
transported.
5.1.3
Relevant material must not be sent to an establishment within England, Wales or
Northern Ireland that does not have an HTA Licence unless one of the exemptions
above applies. Doing so could seriously jeopardise Cardiff University’s HTA
Licence(s) and may have legal implications.
5.1.4
For information on the export of human tissue to establishments outside England,
Wales and Northern Ireland, see the Cardiff University HTA Standard Operating
Procedure for the Import and Export of Human Tissue.
5.2
Consent
5.2.1
Consent from the donor to transport the tissue must be in place prior to
transportation, whether this is to establishments within England, Wales and Northern
Ireland or exported to establishments outside England, Wales and Northern Ireland.
5.2.2
If consent was not in place to transport the tissue, and it was not feasible to approach
the donors for consent, the tissue could be transported providing it was from the
living, anonymised and NRES approval to transport the samples had been obtained.
5.2.3
NRES approval could be sought to transport tissue even if the original project did not
require NRES approval.
5.2.4
If the tissue was from the deceased consent must be in place to transport the
samples; it is not an option to obtain NRES approval to transport tissue from the
deceased in place of obtaining consent.
5.3
Health and Safety Issues in Transporting Human Tissue
5.3.1
Cardiff University policies and procedures from the Occupational Safety, Health and
Environment Unit must be followed when handling or transporting human tissue and
refrigerants.
CU/09/HTA 05/3.0
Page 6 of 16
5.3.2
All processes involving the handling and transportation of human tissues must be
subject to risk assessment and made available to everyone involved. Risk
assessments must cover risks to the tissue in addition to the individual. For further
information on risk assessments see Cardiff University HTA Standard Operating
Procedure for Risk Management and Contingency Planning.
5.3.3
Workers handling the tissues must have training and health screening as
appropriate.
5.3.4
Care must be taken when handling heavy or bulky containers, personnel involved in
their transport should be trained in handling techniques.
5.3.5
Suitable labelling including biohazard warnings must be affixed to each container.
5.3.6
Reagents used in preserving and fixing tissues are harmful and consideration must
be given to the safe handling of these reagents.
5.4
Transportation Records and Documentation
5.4.1
A Material Transfer Agreement (MTA) needs to be in place for any outgoing or
incoming tissue. The MTA should define how the human tissue will be preserved, any
potential contamination risks associated with it and who will be responsible for
disposal. The MTA must be signed on behalf of the University/UHB not by an
individual researcher. All University MTAs need to go through Research and
Commercial Division before being used.
5.4.2
Evidence of an HTA Licence or the exemption must be provided before the tissue is
transported to establishments within England, Wales or Northern Ireland.
5.4.3
Human tissue samples must be tracked and recorded from collection to disposal. A
record must be kept of all tissue that is transported, including where it went, how
much, when it was transported and who was responsible for the transport and receipt
of the tissue.
5.4.4
A risk assessment for the transportation of the tissue from the perspective of the
tissue would need to be written and read by all involved in the tissue transportation.
5.4.5
Appropriate modes of transport, suitable routes and arrangements with people
involved must be planned and arranged in advance, and considered when preparing
risk assessments. A record should be kept of all transportation arrangements,
including contracts with third parties.
5.5
Transport Regulations – Infectious Substances
5.5.1
The World Health Organization (WHO) document ‘Guidance on Regulations for the
Transport of Infectious Substances 2011-2012’, is based on the 16th revised edition
of the United Nations Recommendations on the Transport of Dangerous Goods.
5.5.2
The WHO guidance describes the hazard classification, appropriate labelling and
handling of such substances; a flowchart included in the guidance for the
classification of infectious substances and patient specimens can be found in
Appendix A.
CU/09/HTA 05/3.0
Page 7 of 16
5.5.3
The WHO guidance has been incorporated into this document and must be followed
when transporting human tissue, both nationally and internationally; Sections 5.5 and
5.8 of this SOP contain extracts from the guidance. The full document can be
accessed via the following link:
http://www.who.int/ihr/publications/who_hse_ihr_20100801/en/
5.5.4
Category A Infectious Substances: An infectious substance which is transported in
a form that, when exposure to it occurs, is capable of causing permanent disability,
life-threatening or fatal disease in otherwise health humans or animals. Examples of
such substances can be found in the WHO Guidance on Regulation for the Transport
of Infectious Substances 2011-2012.
5.5.5
5.5.6
.1
Infectious substances that cause disease in humans or both human and
animals should be assigned to United Nations number UN 2814. Infectious
substances that cause disease only in animals should be assigned to UN
2900. These numbers must be clearly displayed on the external outer surface
of the package.
.2
The proper shipping name for UN2814 is INFECTIOUS SUBSTANCE,
AFFECTING HUMANS. The proper shipping name for UN 2900 is
INFECTIOUS SUBSTANCE, AFFECTING ANIMALS only.
.3
Assignment to UN 2814 or UN 2900 should be based on the known medical
history and symptoms of the source human, endemic local conditions, or
professional judgement concerning individual circumstances of the source
human.
.4
Infectious substances in Category A must be transported in packaging that
meets the United Nations class 6.2 specifications and complies with Packing
Instruction P620. Full details of the packaging required for Category A
substances can be found in the WHO Guidance on Regulation for the
Transport of Infectious Substances 2011-2012.
Category B Infectious Substances: An infectious substance that does not meet the
criteria for inclusion in Category A.
.1
Infectious substances in Category B should be assigned to UN 3373 using
the proper shipping name BIOLOGICAL SUBSTANCE, CATEGORY B. This
information must be clearly visible on the external surface of the outer
packaging.
.2
Infectious substances in Category B must be transported in packaging which
complies with Packing Instruction P650. Full details of the packaging required
for Category B substances can be found in the WHO Guidance on Regulation
for the Transport of Infectious Substances.
Exempt Human Specimen: Human specimens for which there is minimal likelihood
that pathogens are present.
.1
Exempt human specimens are not subject to the WHO regulations if the
specimen is transported in a package which will prevent any leakage and
which is marked with the words “Exempt Human Specimen”.
.2
The packaging for Exempt Human Specimens should meet the following
conditions:
CU/09/HTA 05/3.0
Page 8 of 16
(a) The packaging should consist of three components (see section 5.6 for
more detail):
1) leak-proof primary receptacle(s)
2) leak-proof secondary packaging; and
3) an outer packaging of adequate strength for its capacity, mass and
intended use, and with at least one surface having minimum
dimensions of 100mm x 100mm;
(b) For liquids, absorbent material in sufficient quantity to absorb the entire
contents should be placed between the primary receptacle(s) and the
secondary packaging so that, during transport, any release or leak of a
liquid substance will not reach the outer packaging and will not
compromise the integrity of the cushioning material;
(C) When multiple fragile primary receptacles are placed in single secondary
packaging, they should either be individually wrapped or separated to
prevent contact between them.
.3
An element of professional judgement is required to determine if a substance
is exempt under this paragraph. That judgement should be based on the
known medical history and symptoms of the source human or animal and
endemic local conditions.
5.6
Containment/Packaging
5.6.1
Details of the containment requirements for transporting Category A and Category B
infectious substances can be found in the WHO Guidance on Regulation for the
Transport of Infectious Substances 2011-2012.
5.6.2
There are three levels of basic containment required when transporting all other
human tissue samples: primary containment, secondary containment and outer
packaging. Below are the minimum precautions necessary for each level.
5.6.3
Primary Containment
5.6.4
.1
Tissues must be held in suitable containment able to withstand the planned
mode of transport and possible accidents, in conjunction with secondary
containment or further packaging.
.2
Primary containers must be break resistant and leak proof. The nature of the
tissue and the project will largely determine the optimum choice of container.
.3
The primary container must bear appropriate labelling.
Secondary Containment
.1
Secondary containers must be able to hold the primary containers securely
and be able to withstand the planned mode of transport.
.2
Secondary containers must also be suitable for the containment of any
refrigerants being used, e.g. liquid nitrogen, dry ice, water ice.
CU/09/HTA 05/3.0
Page 9 of 16
5.6.5
.3
The container must bear appropriate labelling, including hazard information
and emergency contact details.
.4
Secondary containers must be leak proof and have adequate locks, seals or
catches, able to prevent the accidental release of contents during transport.
.5
There should be sufficient absorbent material to absorb the fluid form all the
primary containers in the case of breakage.
.6
Processes must be in place to ensure that there is no contamination to any
external surfaces of secondary containment.
Outer Packaging
.1
Outer packaging must be sufficiently robust to withstand the planned mode of
transport.
.2
The outer packaging must bear appropriate labelling, including hazard
information and emergency contact details.
5.7
Containment Labelling and Documentation
5.7.1
Each level of containment must be labelled sufficiently and correctly. Specific labels
are required for Category A and Category B Infectious Substances, for further
information see the WHO Guidance on Regulations for the Transport of Infectious
Substances 2011-2012.
5.7.2
Below are the minimum labels necessary for each level of containment for
substances not considered to be Category A or Category B:
5.7.3
Labelling on Primary Containment
All labelling must be sufficiently robust to withstand the planned storage method and
transport while remaining fully legible.
If a sample has already been assigned a sample ID, this should be affixed to the
primary container for transportation; the sample ID should be unique and should not
contain any donor identifiers.
If an anonymous sample is being transported prior to allocating a sample ID, e.g.
following collection from a source hospital, and no other relevant information is
associated with the sample that would render the sample useless if it became
dissociated, transportation without a sample ID on the primary container is permitted.
However all labelling and information on the secondary and outer packaging must be
in full.
5.7.4
Labelling on Secondary Containment
.1
All labelling must be able to withstand the planned mode of transport.
.2
The container should be clearly labelled with any relevant hazard signage.
Where necessary this should include a warning sign, e.g. ”Do Not Open,
please observe emergency procedures“.
CU/09/HTA 05/3.0
Page 10 of 16
5.7.5
.3
Information giving full destination details including the name of the Principal
Investigator must be clearly displayed.
.4
Documentation must be attached to the container providing a description and
identification details of the tissue (if relevant), the address of both source and
destination establishments, details of any hazardous contents, and
emergency procedures, including at least 3 contact numbers and addresses.
This may be in a sealed envelope, which may be opened in an emergency.
Labelling on Outer packaging
.1
Any outer packaging should have similar information to secondary
containment.
.2
If transport is undertaken by a third party (e.g. special courier), the guidelines
supplied by the third party must also be followed.
.3
If transporting material in dry ice or liquid nitrogen, specific signage is
required to comply with legislation (see Section 5.8 for more information).
5.8
Dangerous Goods and Packing Instructions
5.8.1
Aside from infectious substances there are a number of other substances that may
be used for transporting human tissue that could be considered ‘Dangerous Goods’.
5.8.2
The Air Navigation (Dangerous Goods) Regulations 2002 make detailed
requirements for the carriage of ‘Dangerous Goods’ which means any article or
substance identified as such in the Technical Instructions approved and published by
the International Civil Aviation Organization, such as an infectious substances or dry
ice packaging.
5.8.3
If a Category A substance is packed in dry ice, the dry ice needs to be included
alongside the Infectious Substance on the ‘Declaration of Dangerous Goods’ and the
outer packaging needs to contain the UN1845 hazard label. The packing instruction
P003 (ICAO/IATA P1954) should be followed.
5.8.4
If a Category B or Exempt substance is packed in dry ice, the package should be
marked “Carbon dioxide, solid” or “Dry ice”. The packing instruction P003
(ICAO/IATA P1954) should be followed.
5.8.5
If liquid nitrogen is used as a refrigerant, special arrangements should be made in
advance with the carrier. The hazard label for liquid nitrogen should be attached to
the outer packaging and, if carried by air, the handling label for cryogenic liquids
should also be affixed.
5.8.6
Dry Shippers do not contain free liquid nitrogen and are not a regulated dangerous
good; the hazard label is therefore not required. However the classification of
infectious substance must be properly marked on the outer packaging and included
in the Dangerous Goods Declaration for Category A substances or contained on the
Air Waybill for Category B or Exempt Packages.
CU/09/HTA 05/3.0
Page 11 of 16
5.9
Transportation Methods
5.9.1
A specialist courier would always be the preferred option for transporting human
tissue. The courier would ease the burden of sending tissue samples as they should
arrange and/or ensure the correct paperwork and labelling were in pace.
5.9.2
There are a number of methods for transporting human tissue. Below are the
minimum precautions necessary for each method.
5.9.3
Transport by Sea and Air
5.9.4
5.9.5
.1
Where possible, the use of a professional courier service is recommended,
especially when transporting internationally.
.2
The precise nature of the material being transported will determine
appropriate procedures to be followed, advice will need to be obtained from
the transport operator.
.3
Hand carriage, including hand luggage, checked in baggage or upon the
person, of Category A or Category B infectious substances is strictly
prohibited by international air carriers.
.4
Regulations relating to the use of human tissue in the destination country
must be consulted when planning transportation.
.5
The transport operator and HM Revenue and Customs should be contacted
prior to transport to determine the appropriate conditions for transport.
.6
HTA guidelines on the import and export of human tissues should be
observed, see HTA Code of Practice 8: Import and Export of Human Bodies,
Body Parts and Tissue and the Cardiff University HTA Standard Operating
Procedure for the Import and Export of Human Tissue.
Transport by Post
.1
Postal transport of Category A infectious substances is strictly prohibited.
.2
Postal transport of Category B infectious substances are prohibited in the
international post, but may be carried within the UK provided strict conditions
are met. Samples must be packaged in accordance with Packing Instruction
P650.
.3
There are several commercially available packing systems that are fully
compliant with Packing Instructions P650 and the requirements of Category B
infectious substances, including the Royal Mail ‘Safebox’.
.4
Postal transport of dry ice is prohibited.
Transporting by Hand or Road
.1
Secondary/outer packaging must be suitably labelled.
.2
Secondary/outer packaging must be sufficiently robust to contain material in
the event of an accident.
CU/09/HTA 05/3.0
Page 12 of 16
5.9.6
6
.3
The material must never be left unattended.
.4
Instructions for action in an emergency must be clearly indicated.
.5
The University’s policy relating to the use of personal and hire vehicles must
be observed, for further information see Cardiff University Occupational
Health, Safety and Environment Unit.
.6
Cryogenic gases, such as dry ice, must be kept separate from the driver and
passengers. Vehicles with a separate cab (e.g. pick-up truck) or vehicles with
a separate trailer are essential. Cryogenic gases should never be transported
in cars.
.7
Cardiff University policies and procedures from the Occupational Safety,
Health and Environment Unit must be followed when handling or transporting
human tissue and refrigerants.
.8
Transportation of human tissue using public transport is not recommended.
Use of Third Parties for Transport
.1
Only specialist couriers with established procedures for transporting human
material should be used for transporting fresh unfixed material.
.2
Embedded blocks, slides etc may be transported by secure courier services.
.3
A secure tracking system must be in place from sender to a specified
recipient.
.4
The recipient must either be:
a) compliant with HTA legislation and authorised to receive the tissue
under an individual licence, satellite licence or under NRES ethical
approval, unless otherwise exempt from HTA licensing, or
b) compliant with the regulations in force in the destination country.
These regulations must be determined in advance of transport
arrangements.
REFERENCES




Cardiff University Occupational Safety, Health and Environment Unit:
http://www.cardiff.ac.uk/osheu/safety/index.html
HTA Codes of Practice:
http://www.hta.gov.uk/legislationpoliciesandcodesofpractice/codesofpractice.c
fm
International Civil Aviation Organization, Technical Instructions for the Safe
Transport of Dangerous Good by Air:
http://www.icao.int/safety/DangerousGoods/Pages/technical-instructions.aspx
The Air Navigation (Dangerous Goods) Regulations 2002:
http://www.legislation.gov.uk/uksi/2002/2786/contents/made
CU/09/HTA 05/3.0
Page 13 of 16



7
UN Recommendations on the Transport of Dangerous Goods - Model
Regulations Sixteenth revised edition:
http://www.unece.org/trans/danger/publi/unrec/rev16/16files_e.html
WHO Guidance on Regulations for the Transport of Infectious Substances:
http://www.who.int/ihr/publications/who_hse_ihr_20100801/en/
REFERENCED SOPs




Cardiff University HTA SOP Obtaining Informed Consent [CU/09/ HTA 02/3.0]
Cardiff University HTA SOP Management of Records [CU/09/ HTA 06/3.0]
Cardiff University HTA SOP Risk Management and Contingency Planning
[CU/11/ HTA 10/3.0]
Cardiff University HTA SOP Import and Export of Human Tissue [CU/13/ HTA
13/1.0]
CU/09/HTA 05/3.0
Page 14 of 16
8
CONTACTS
8.1
DI and PDs
Name
School/
UHB
Coverage
Email
Tel
Prof Jonathan Bisson
DI
CU/UHB
All areas
BissonJI@cf.ac.uk
(207)43742
ARUK
BBC
BIOSI
LongmanAJ1@cf.ac.uk
EdwardsWD@cf.ac.uk
(208)75419
(208)75136
DENTL
DENTL
DENTL
DENTL
StephensP@cf.ac.uk
ChadwickBL@cf.ac.uk
WhiteFS@cf.ac.uk
Gilmour@cf.ac.uk
(207)42529
(207)46569
(207)42546
(207)42617
PATHY
AML and
HAEMY
Jasani@cf.ac.uk
(207)42700
WhitePC@cf.ac.uk
(207)44524
PowellNG@cf.ac.uk
(207)44742
IdziaszczykSA1@cf.ac.uk
(206)87859
Bowden@cf.ac.uk
GregoryC1@cf.ac.uk
MantripragadaKK@cf.ac.uk
Topley@cf.ac.uk
(206)87302
(206)87221
(206)87063
(207)43770
ITIME
MOLEX
HanzelK@cf.ac.uk
DayanCM@cf.ac.uk
(207)42050
(207)42182
MOLEX
SURGY
Tenovus
Building
OPTOM
PHRMY
Med Gen
PowellW1@cf.ac.uk
MartinTA1@cf.ac.uk
(207)48497
(207)46536
WangEC@cf.ac.uk
AlbonJ@cf.ac.uk
BirchallJC@cf.ac.uk
Ian.Frayling@wales.nhs.uk
(206)87318
(208)75427
(208)75815
(207) 44203
Dr Andrea Longman
Mr Bill Edwards
Prof Bharat Jasani
BIOSI PD
BIOSI PD
DENTL
Lead PD
DENTL PD
DENTL PD
DENTL PD
MEDIC
Lead PD
Dr Paul White
MEDIC PD
Dr Ned Powell
MEDIC PD
Prof Phil Stephens
Prof Barbara Chadwick
Dr Fiona Gagg
Dr Alan Gilmour
Mrs Shelley Idziaszczyk MEDIC PD
Dr Paul Bowden
Dr Clive Gregory
Dr Kiran Mantripragada
Prof Nick Topley
Dr Wendy Powell
Dr Tracey Martin
MEDIC PD
MEDIC PD
MEDIC PD
MEDIC PD
MEDIC PD
(assistant)
MEDIC PD
MEDIC PD
(assistant)
MEDIC
Dr Eddie Wang
Dr Julie Albon
Dr James Birchall
Dr Ian Frayling
MEDIC PD
OPTOM PD
PHRMY PD
UHB
Mr Karl Hanzel
Prof Colin Dayan
8.2
ICAGE/
GYNON
ICAGE/
MGENE
INIIM in
HWB
IPCPH
IPMCN
ITIME
HT Act Compliance Team
Name
Division
Position
Email
Tel
Mrs Sharon Orton
GOVRN
HTA Co-ordinator
HTA@cf.ac.uk
(208)74888
Dr Carina Hibbs
GOVRN
Governance Officer HTA@cf.ac.uk
(208)70231
Mrs Pat Tamplin
UHB
Governance Officer Pat.Tamplin@wales.nhs.uk
(207)45879
CU/09/HTA 05/3.0
Page 15 of 16
APPENDIX A
WHO Flowchart for the Classification of Infectious Substances and Patient Samples
© World Health Organization 2010
CU/09/HTA 05/3.0
Page 16 of 16